UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 10-Q/A*
Quarterly Report Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
| For the Quarter ended June 30, 2004 | Commission File Number: 000-23092 |
NATIONAL DENTEX CORPORATION
| Massachusetts | 04-2762050 | |
| (State of Incorporation) | (I.R.S. Identification No.) |
| 526 Boston Post Road, Wayland, MA | 01778 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(508) – 358 – 4422
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and has been subject to such filing requirements for the past 90 days.
Yesþ Noo
*Amendment to Part I, Item 1, Item 2, and Item 4 as set forth herein.
EXPLANATORY NOTE
As previously discussed in our press release dated May 9, 2005 and our Current Report on Form 8-K filed with the SEC on May 12, 2005, we are filing this Amendment No. 2 to our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004 as during the process of closing our accounting records for fiscal 2004 and preparing our corresponding Annual Report on Form 10-K we determined that we needed to restate the condensed consolidated financial statements contained in our previously filed Quarterly Reports on Form 10-Q for each of the first three fiscal quarters of 2004 to revise the accounting for intangible assets recorded in connection with certain acquisitions. In the process of analyzing all subject acquisitions we identified two intangible assets that we had not previously recognized apart from goodwill: customer relationships and trade names. The accounting treatment for these intangible assets requires amortization expense over the estimated economic useful life for customer relationships and impairment testing and associated expense, if any, for trade names. In addition, we have determined that we need to revise the classification of these intangible assets within the condensed consolidated balance sheets of our financial statements.
While we concluded that the adjustments required by this restatement are not material to any of our previously filed Quarterly Reports on Form 10-Q, the significance of the cumulative adjustment of approximately $292,000, or $.06 per share on a diluted basis, precluded it from being recorded solely in the fourth quarter of 2004, thereby necessitating amendments to our prior filings on Form 10-Q made with respect to the first three quarters of fiscal 2004.
Accordingly, we are filing this Amendment No. 2 to our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004 to amend Part I, Item 1 (Financial Statements) and Part I, Item 2 (Management’s Discussion and Analysis of Financial Condition and Results of Operations). We are also amending Part I, Item 4 (Controls and Procedures).
The aggregate effect of these adjustments is summarized in footnote 2 of the condensed consolidated financial statements included in this Form 10-Q/A. In addition, on December 10, 2004 we announced a three-for-two stock split in the form of a stock dividend on our common stock to be paid on December 31, 2004 to stockholders of record on December 20, 2004. All references in the financial statements and notes to number of shares, per share amounts, stock option data and market prices have been adjusted to reflect this stock split.
2
NATIONAL DENTEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| December 31, | June 30, | |||||||
| 2003 | 2004 | |||||||
| (Restated) | ||||||||
| ASSET | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 1,835,471 | $ | 1,952,543 | ||||
| Accounts receivable: | ||||||||
| Trade, less allowance of $313,000 in 2003 and $282,000 in 2004 | 11,497,927 | 12,950,588 | ||||||
| Other | 416,093 | 507,912 | ||||||
| Inventories, net | 5,996,483 | 5,823,979 | ||||||
| Prepaid expenses | 1,702,632 | 2,551,965 | ||||||
| Deferred tax asset, current | 481,539 | 519,130 | ||||||
| Total current assets | 21,930,145 | 24,306,117 | ||||||
| PROPERTY, PLANT AND EQUIPMENT: | ||||||||
| Land and buildings | 4,620,571 | 6,584,464 | ||||||
| Leasehold and building improvements | 6,953,659 | 6,997,878 | ||||||
| Laboratory equipment | 11,328,266 | 11,687,987 | ||||||
| Furniture and fixtures | 4,617,170 | 4,774,312 | ||||||
| 27,519,666 | 30,044,641 | |||||||
| Less — Accumulated depreciation and amortization | 14,169,829 | 15,071,866 | ||||||
| Net property, plant and equipment | 13,349,837 | 14,972,775 | ||||||
| OTHER ASSETS, net: | ||||||||
| Goodwill | 27,476,637 | 28,188,039 | ||||||
| Trade names | 2,580,000 | 2,503,000 | ||||||
| Customer relationships | 2,143,271 | 1,954,639 | ||||||
| Non-competition agreements | 2,838,676 | 2,628,025 | ||||||
| Other assets | 3,670,427 | 4,215,616 | ||||||
| Total other assets | 38,709,011 | 39,489,319 | ||||||
| Total assets | $ | 73,988,993 | $ | 78,768,211 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 1,778,288 | $ | 2,007,316 | ||||
| Accrued liabilities: | ||||||||
| Payroll and employee benefits | 5,106,325 | 5,815,526 | ||||||
| Current portion of deferred purchase price | 2,391,951 | 1,497,894 | ||||||
| Other accrued expenses | 401,252 | 843,995 | ||||||
| Total current liabilities | 9,677,816 | 10,164,731 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Payroll and employee benefits | 1,981,751 | 2,227,010 | ||||||
| Deferred purchase price | 304,162 | 305,388 | ||||||
| Deferred tax liability, non-current | 1,885,003 | 1,819,339 | ||||||
| Total long-term liabilities | 4,170,916 | 4,351,737 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Preferred stock, $.01 par value | ||||||||
| Authorized - 500,000 shares | ||||||||
| None issued and outstanding | — | — | ||||||
| Common stock, $.01 par value | ||||||||
| Authorized - 8,000,000 shares | ||||||||
| Issued - 5,536,533 shares at December 31, 2003 and 5,582,890 shares at June 30, 2004 | ||||||||
| Outstanding - 5,147,125 shares at December 31, 2003 and 5,193,482 shares at June 30, 2004 | 36,911 | 37,219 | ||||||
| Paid-in capital | 17,034,343 | 17,542,227 | ||||||
| Retained earnings | 48,187,945 | 51,791,235 | ||||||
| Treasury stock at cost - 389,408 shares at December 31, 2003 and June 30, 2004 | (5,118,938 | ) | (5,118,938 | ) | ||||
| Total stockholders’ equity | 60,140,261 | 64,251,743 | ||||||
| Total liabilities and stockholders’ equity | $ | 73,988,993 | $ | 78,768,211 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
NATIONAL DENTEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||
| 2003 | 2004 | 2003 | 2004 | |||||||||||||
| (Restated) | (Restated) | |||||||||||||||
| Net sales | $ | 25,181,837 | $ | 28,831,120 | $ | 49,147,132 | $ | 56,759,310 | ||||||||
| Cost of goods sold | 14,876,595 | 16,829,279 | 29,286,411 | 33,159,580 | ||||||||||||
| Gross profit | 10,305,242 | 12,001,841 | 19,860,721 | 23,599,730 | ||||||||||||
| Selling, general and administrative expenses | 7,527,718 | 8,517,139 | 14,872,162 | 17,401,911 | ||||||||||||
| Operating income | 2,777,524 | 3,484,702 | 4,988,559 | 6,197,819 | ||||||||||||
| Other expense | 75,702 | 108,051 | 128,494 | 174,629 | ||||||||||||
| Interest (income) expense | (6,994 | ) | 6,771 | (15,622 | ) | 17,706 | ||||||||||
| Income before provision for income taxes | 2,708,816 | 3,369,880 | 4,875,687 | 6,005,484 | ||||||||||||
| Provision for income taxes | 1,058,469 | 1,347,953 | 1,893,717 | 2,402,194 | ||||||||||||
| Net income | $ | 1,650,347 | $ | 2,021,927 | $ | 2,981,970 | $ | 3,603,290 | ||||||||
| Net income per share – basic | $ | .32 | $ | .39 | $ | .58 | $ | .70 | ||||||||
| Net income per share – diluted | $ | .32 | $ | .37 | $ | .58 | $ | .66 | ||||||||
| Weighted average shares outstanding – basic | 5,131,765 | 5,179,503 | 5,118,228 | 5,165,698 | ||||||||||||
| Weighted average shares outstanding – diluted | 5,194,994 | 5,466,998 | 5,182,068 | 5,422,841 | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
NATIONAL DENTEX CORPORATION
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
| Common Stock | ||||||||||||||||||||||||
| Number of | $.01 Par | Paid-in | Retained | Treasury | ||||||||||||||||||||
| Shares | Value | Capital | Earnings | Stock | Total | |||||||||||||||||||
| BALANCE, December 31, 2003 | 5,536,533 | $ | 36,911 | $ | 17,034,343 | $ | 48,187,945 | $ | (5,118,938 | ) | $ | 60,140,261 | ||||||||||||
| Issuance of 19,121 shares of common stock under the stock option plans | 19,121 | 127 | 222,712 | — | — | 222,839 | ||||||||||||||||||
| Issuance of 27,236 shares of common stock under the stock purchase plan | 27,236 | 181 | 285,172 | — | — | 285,353 | ||||||||||||||||||
| Net income (Restated) | — | — | — | 3,603,290 | — | 3,603,290 | ||||||||||||||||||
| BALANCE, June 30, 2004 (Restated) | 5,582,890 | $ | 37,219 | $ | 17,542,227 | $ | 51,791,235 | $ | (5,118,938 | ) | $ | 64,251,743 | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
NATIONAL DENTEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| For the Six Months Ended | ||||||||
| June 30, | June 30, | |||||||
| 2003 | 2004 | |||||||
| (Restated) | ||||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 2,981,970 | $ | 3,603,290 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities, net of effects of acquisitions: | ||||||||
| Depreciation and amortization | 1,128,805 | 1,502,974 | ||||||
| Impairment of long-lived assets | — | 77,000 | ||||||
| Provision (benefit) for deferred income taxes | 2,212 | (44,630 | ) | |||||
| Provision for bad debts | 50,864 | 22,411 | ||||||
| Changes in operating assets and liabilities, net of effects of acquisitions: | ||||||||
| Increase in accounts receivable | (952,004 | ) | (1,541,749 | ) | ||||
| Decrease in inventories | 14,960 | 181,069 | ||||||
| Increase in prepaid expenses | (140,811 | ) | (849,333 | ) | ||||
| Increase in other assets | (607,993 | ) | (1,267,037 | ) | ||||
| Increase in accounts payable and accrued liabilities | 60,523 | 2,158,995 | ||||||
| Net cash provided by operating activities | 2,538,526 | 3,842,990 | ||||||
| Cash flows from investing activities: | ||||||||
| Payment for acquisitions, net of cash acquired | (507,414 | ) | (117,000 | ) | ||||
| Payment of deferred purchase price | (915,925 | ) | (1,636,740 | ) | ||||
| Additions to property, plant and equipment, net | (1,556,670 | ) | (2,480,370 | ) | ||||
| Net cash used in investing activities | (2,980,009 | ) | (4,234,110 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Issuance of common stock | 309,986 | 508,192 | ||||||
| Net cash provided by financing activities | 309,986 | 508,192 | ||||||
| Net (decrease) increase in cash and cash equivalents | (131,497 | ) | 117,072 | |||||
| Cash and cash equivalents at beginning of period | 5,808,435 | 1,835,471 | ||||||
| Cash and cash equivalents at end of period | $ | 5,676,938 | $ | 1,952,543 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Interest paid | $ | 5,937 | $ | 18,563 | ||||
| Income taxes paid | $ | 1,286,353 | $ | 2,228,059 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
NATIONAL DENTEX CORPORATION
Notes to Condensed Consolidated Financial Statements
June 30, 2004
(1) Interim Financial Statements
The accompanying unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results of operations for the periods presented. Interim results are not necessarily indicative of the results to be expected for a full year.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s condensed consolidated financial statements for the year ended December 31, 2003 as filed with the SEC on Form 10-K. Certain amounts in the financial statements for the year ended December 31, 2003 have been reclassified to conform to the current period presentation.
(2) Restatement of prior financial information
In connection with its accounting for purchase business combinations, the Company had not historically recognized certain identifiable intangible assets, specifically customer relationships and trade names, apart from goodwill. However, in 2004 based upon a re-examination of the applicable accounting literature, FASB issued Statement No. 141 (SFAS 141),“Business Combinations”, FASB issued Statement No. 142 (SFAS 142),“Goodwill and Other Intangible Assets”and Emerging Issues Task Force Abstract 02-17“Recognition of Customer Relationship Intangible Assets Acquired in a Business Combination”(EITF 02-17), the Company determined that the proper accounting practice is to recognize customer relationships and trade names as separate identifiable intangible assets apart from goodwill in acquisitions consummated by the Company subsequent to the applicable effective dates of SFAS 141 and EITF 02-17.
Accordingly, the Company has revised its classification of intangible assets, and the associated income tax liabilities in the condensed consolidated balance sheets, which resulted in the recognition, apart from goodwill, of $2,143,271 and $2,580,000 of customer relationships and trade names, respectively, as of December 31, 2003. As part of the revised classification, the Company recorded a deferred tax liability of $1,756,400 which relates to the book versus tax basis difference associated with these customer relationships and trade name assets. The deferred tax liability was recorded as a component of the Company’s purchase accounting for these acquisitions and accordingly increased goodwill by a corresponding amount. The impact of this revised classification and the recognition of the associated income tax liabilities to the condensed consolidated balance sheet was not material.
The effect of recognizing customer relationship and trade name intangibles apart from goodwill resulted in out of period charges in the first quarter of 2004 for amortization expense of $70,000 and impairment charges of $77,000. The impact of these out of period charges to the consolidated statements of income and cash flows for fiscal 2002, 2003 and 2004 was not material. However, because the cumulative impact, if recorded in the fourth quarter of fiscal 2004, would have been material to net income for the fourth quarter of 2004, the Company restated its condensed consolidated financial statements for the quarters ended March 31, 2004, June 30, 2004 and September 30, 2004 as reported in Forms 10-Q/A. The effect of these out of period charges and current period amortization expense for the three and six-months ended June 30, 2004 of $60,000 and $119,000, respectively, has been summarized as follows:
7
Notes to Condensed Consolidated Financial Statements (Continued)
| As Previously | As | |||||||||||
| Reported | Restated | |||||||||||
| Three Months Ended | Three Months Ended | |||||||||||
| June 30, 2004 | Adjustments | June 30, 2004 | ||||||||||
Condensed Consolidated Balance Sheets | ||||||||||||
| Customer relationships, net of amortization expense | $ | — | $ | 1,954,639 | $ | 1,954,639 | ||||||
| Trade names, net of impairment charges | — | 2,503,000 | 2,503,000 | |||||||||
| Goodwill | 31,154,910 | (2,966,871 | ) | 28,188,039 | ||||||||
| Deferred income tax liability – non current | 169,192 | 1,650,147 | 1,819,339 | |||||||||
| Retained earnings | 51,950,615 | (159,380 | ) | 51,791,235 | ||||||||
Condensed Consolidated Statements of Income | ||||||||||||
| Selling, general and administrative expenses | 8,457,604 | 59,535 | 8,517,139 | |||||||||
| Operating income | 3,544,237 | (59,535 | ) | 3,484,702 | ||||||||
| Income before provision for income taxes | 3,429,415 | (59,535 | ) | 3,369,880 | ||||||||
| Provision for income taxes | 1,371,766 | (23,813 | ) | 1,347,953 | ||||||||
| Net income | 2,057,649 | (35,722 | ) | 2,021,927 | ||||||||
| Net income per share — basic | .40 | (.01 | ) | .39 | ||||||||
| Net income per share — diluted | .38 | (.01 | ) | .37 | ||||||||
| As Previously | As | |||||||||||
| Reported | Restated | |||||||||||
| Six Months Ended | Six Months Ended | |||||||||||
| June 30, 2004 | Adjustments | June 30, 2004 | ||||||||||
Condensed Consolidated Balance Sheets | ||||||||||||
| Customer relationships, net of amortization expense | $ | — | $ | 1,954,639 | $ | 1,954,639 | ||||||
| Trade names, net of impairment charges | — | 2,503,000 | 2,503,000 | |||||||||
| Goodwill | 31,154,910 | (2,966,871 | ) | 28,188,039 | ||||||||
| Deferred income tax liability — non current | 169,192 | 1,650,147 | 1,819,339 | |||||||||
| Retained Earnings | 51,950,615 | (159,380 | ) | 51,791,235 | ||||||||
Condensed Consolidated Statements of Income | ||||||||||||
| Selling, general and administrative expenses | 17,136,279 | 265,632 | 17,401,911 | |||||||||
| Operating income | 6,463,451 | (265,632 | ) | 6,197,819 | ||||||||
| Income before provision for income taxes | 6,271,116 | (265,632 | ) | 6,005,484 | ||||||||
| Provision for income taxes | 2,508,446 | (106,252 | ) | 2,402,194 | ||||||||
| Net income | 3,762,670 | (159,380 | ) | 3,603,290 | ||||||||
| Net income per share — basic | .73 | (.03 | ) | .70 | ||||||||
| Net income per share — diluted | .69 | (.03 | ) | .66 | ||||||||
8
Notes to Condensed Consolidated Financial Statements (Continued)
(3) Goodwill and Other Intangible Assets
Goodwill and Other Indefinite-Lived Intangible Assets Not Subject to Amortization
In accordance with SFAS 142; goodwill amortization ceased on December 31, 2001. The Company continually evaluates whether events and circumstances have occurred that indicate that the value of goodwill has been impaired. In accordance with SFAS 142, goodwill is evaluated for possible impairment on an annual basis, based on a two-step process. The first step is to compare the fair value of the reporting unit to its carrying amount to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, the second step would be to record an impairment loss to the extent of that difference. The Company determines fair value using factors based on revenue and operating margins. There has been no impairment of goodwill in 2002, 2003 or 2004.
Additionally, the Company also recognizes the existence of value in trade names acquired in business combinations and believes the useful life of this intangible to be indefinite. Accordingly, trade names are also evaluated for impairment on an annual basis in accordance with SFAS No. 142. Impairment charges related to trade names are recognized when the fair value is less than the carrying value of the asset. Impairment charges related to trade names were recorded in the quarter ended March 31, 2004 in the amount of $77,000, which relates to prior periods. Trade name impairment charges resulted from a decline in forecasted revenue at specific laboratories in comparison to revenue forecasts used in previous valuation calculations.
Intangible Assets Subject to Amortization
Non-competition agreements and customer relationship intangibles arising from dental laboratory acquisitions are amortized over their useful lives. The acquisition date fair value of non-competition agreements are deferred and amortized over their economic useful lives, in accordance with the terms of the agreements, over 2 to 10 years. The acquisition date fair value associated with acquired customer relationships are amortized on a straight-line basis over their estimated useful life, which currently approximates 9 years.
(4) Acquisitions
The Company’s acquisition strategy is to consolidate within the dental laboratory industry and use its financial and operational synergies to create a competitive advantage. Certain factors, such as the laboratory’s technical skills, reputation in the local marketplace and value as a going concern result in the recognition of goodwill.
In connection with these acquisitions, the Company has incurred certain deferred purchase costs relating to non-competition agreements with the former owners and certain other key employees, ranging over periods of 2 to 10 years, and other contingent payments provided for in the purchase agreements.
During the six months ended June 30, 2003 the Company acquired the following dental laboratory operations:
| Acquisition | Form of Acquisition | Location | Period Acquired | |||||||||
| Nobilium of Texas | Certain Assets | Houston,TX | March 2003 | |||||||||
| Accurate Dental Laboratory | Certain Assets | Albuquerque,NM | April 2003 | |||||||||
| Jackson Dental Laboratory | Certain Assets | Orlando, FL | April 2003 | |||||||||
During the six months ended June 30, 2004 the Company acquired the following dental laboratory operations:
| Acquisition | Form of Acquisition | Location | Period Acquired | |||||||||
| Hamlett Dental Laboratory | Certain Assets | Holt, MI | April 2004 | |||||||||
| Dental Arts Laboratory of Dallas | Certain Assets | Dallas, TX | May 2004 | |||||||||
9
Notes to Condensed Consolidated Financial Statements (Continued)
The acquisitions presented above were consolidated into operations at the Company’s existing laboratory facilities. These acquisitions have been reflected in the accompanying condensed consolidated financial statements from the date of acquisition and have been accounted for as purchases in accordance with SFAS No.141, “Business Combinations”. The total purchase price, while not material to the condensed consolidated financial position, results of operations or cash flows in any of the periods presented, has been allocated to the acquired assets and liabilities based on estimates of their fair values. The following pro forma operating results of the Company assume these acquisitions had been made as of January 1, 2003. Such information includes adjustments to reflect additional depreciation, amortization and interest expense and is not necessarily indicative of what the results of operations would actually have been, or the results of operations to be expected in future periods.
| Six Months Ended | ||||||||
| June 30, | June 30, | |||||||
| 2003 | 2004 | |||||||
| Net sales | $ | 49,600,000 | $ | 56,892,000 | ||||
| Net income | 3,045,000 | 3,623,000 | ||||||
| Net income per share: | ||||||||
| Basic | $ | .59 | $ | .70 | ||||
| Diluted | $ | .59 | $ | .67 | ||||
(5) Stock Split
On December 10, 2004 the Company announced a three-for-two stock split in the form of a stock dividend on its common stock to be paid on December 31, 2004 to stockholders of record on December 20, 2004. All references in the financial statements and notes to number of shares, per share amounts, stock option data and market prices have been adjusted to reflect this stock split.
(6) Earnings Per Share
In accordance with the disclosure requirements of FASB issued Statement No. 128,“Earnings per Share,” basic earnings per share is computed by dividing net income by the weighted average number of shares outstanding and diluted earnings per share reflects the dilutive effect of stock options. The weighted average number of shares outstanding, the dilutive effects of outstanding stock options, and the shares under option plans that were anti-dilutive for the three and six months ended June 30, 2003 and 2004 are as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2003 | 2004 | 2003 | 2004 | |||||||||||||
| Weighted average number of shares used in basic earnings per share calculation | 5,131,765 | 5,179,503 | 5,118,228 | 5,165,698 | ||||||||||||
| Incremental shares under option plans | 63,229 | 287,495 | 63,840 | 257,143 | ||||||||||||
| Weighed average number of shares used in diluted earnings per share calculation | 5,194,994 | 5,466,998 | 5,182,068 | 5,422,841 | ||||||||||||
| Shares under option plans excluded in computation of diluted earnings per share due to anti-dilutive effects | 755,750 | None | 755,750 | None | ||||||||||||
The following table summarizes options that were outstanding but were not included in the computation of diluted earnings per share because the options’ exercise price was greater than the average market price of the common shares:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2003 | 2004 | 2003 | 2004 | |||||||||||||
| Number of Options for Common Shares | 755,750 | None | 755,750 | None | ||||||||||||
| Range of Exercise Prices | $ | 13.01-$16.59 | — | $ | 13.01-$16.59 | — | ||||||||||
| Expire Through: | January 2013 | — | January 2013 | — | ||||||||||||
10
Notes to Condensed Consolidated Financial Statements (Continued)
(7) Stock-Based Compensation
The Company adopted the disclosure provisions of SFAS No. 123,“Accounting for Stock-Based Compensation.”The Company has elected to continue to account for employee stock options at intrinsic value, in accordance with Accounting Principles Board Opinion No. 25,“Accounting for Stock Issued to Employees,”with disclosure of the effects of fair value accounting on net income and earnings per share on a pro forma basis. Had compensation costs for the Company’s 1992 Long-Term Incentive Plan, 2001 Stock Plan and 1992 Employees’ Stock Purchase Plan been determined consistent with SFAS 123, the Company’s net income and earnings per share would have been reduced to the following pro forma amounts:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2003 | 2004 | 2003 | 2004 | |||||||||||||
| (Restated) | (Restated) | |||||||||||||||
| Net income, as reported: | $ | 1,650,347 | $ | 2,021,927 | $ | 2,981,970 | $ | 3,603,290 | ||||||||
| Stock-based employee compensation expense included in reported net income | — | — | — | — | ||||||||||||
| Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects | 77,602 | 38,592 | 170,628 | 82,686 | ||||||||||||
| Pro forma net income | $ | 1,572,745 | $ | 1,983,335 | $ | 2,811,342 | $ | 3,520,604 | ||||||||
| Earnings per share: As reported, basic | $ | .32 | $ | .39 | $ | .58 | $ | .70 | ||||||||
| Pro forma, basic | .31 | .38 | .55 | .68 | ||||||||||||
| As reported, diluted | .32 | .37 | .58 | .66 | ||||||||||||
| Pro forma, diluted | .30 | .36 | .54 | .65 | ||||||||||||
(8) Recent Accounting Pronouncements
In January 2003, the FASB issued FASB Interpretation No. 46,“Consolidation of Variable Interest Entities” (“FIN 46”). This interpretation of Accounting Research Bulletin No. 51, “Consolidated Financial Statements,” addresses consolidation by business enterprises of variable interest entities that possess certain characteristics. FIN 46 requires that if a business enterprise has a controlling financial interest in a variable interest entity, the assets, liabilities, and results of the activities of the variable interest entity must be included in the condensed consolidated financial statements with those of the business enterprise. FIN 46, as revised in December 2003, must be applied at the end of periods ending after June 15, 2004, and is effective immediately for all new variable interest entities created or acquired after January 31, 2003. The adoption of the revised FIN 46 did not have a material impact on the Company’s results of operations or financial position, as the Company is not a party to any variable interest entities at this time. The Company will apply the consolidation requirement of FIN 46 in future periods if the Company should own any interest in any variable interest entity.
(9) Inventories
Inventories consist of the following:
| December 31, 2003 | June 30, 2004 | |||||||
| Raw Materials | $ | 5,000,816 | 4,823,322 | |||||
| Work in Process | 995,667 | 1,000,657 | ||||||
| $ | 5,996,483 | $ | 5,823,979 | |||||
11
Notes to Condensed Consolidated Financial Statements (Continued)
(10) Lines of Credit
The Company has concluded a new financing agreement (the “Agreement”) with Fleet National Bank, a Bank of America company (the “Bank”). The Agreement, dated June 30, 2004, includes a revolving line of credit of $5,000,000 and a revolving acquisition line of credit of $20,000,000. The interest rate on both revolving lines of credit is the prime rate or, at the Company’s option, the London Interbank Offered Rate (“LIBOR”) plus a range of 0.75% to 1.5% depending on the ratio of total liabilities to tangible net worth. Both revolving lines of credit terminate on June 30, 2007.
A commitment fee of one-eighth of 1% per annum is payable on the unused amount of the first revolving line of credit. A facility fee of $10,000 per year is required on the acquisition line of credit. At June 30, 2004, the full principal amount was available to the Company under both facilities. The Agreement requires compliance with certain covenants, including the maintenance of specified net worth and other financial ratios. As of June 30, 2004, the Company was in compliance with these covenants.
The Company had previously maintained a financing agreement with Citizens Bank of Massachusetts that included a revolving credit facility of $4,000,000 and a line of credit facility of $8,000,000. The interest rate on both lines of credit would have been the prime rate minus 0.5% or the London Interbank Offered Rate (“LIBOR”) plus 1.5%, at the Company’s option. Both lines of credit expired as planned on June 30, 2004.
(11) Legal Proceedings
The Company is involved from time to time in litigation incidental to its business. Management believes that the outcome of current litigation will not have a material adverse effect upon the operations or financial condition of the Company and will not disrupt the normal operations of the Company.
(12) Subsequent Events
Effective July 1, 2004, the Company acquired certain assets of the dental laboratories noted below. These laboratories will be consolidated into operations at the Company’s existing laboratory facilities. Aggregated annual sales for these laboratories totaled approximately $700,000.
| Artisan Dental Studio | Lakewood, Colorado | |
| Loyd Dental Studio, LTD | Indianapolis, Indiana | |
| G&S Dental Laboratory, Inc | North Royalton, Ohio |
The Company has reached an agreement in principle to acquire a dental laboratory in a new market area. This acquisition, which is expected to add over $4,000,000 in annual sales volume, is subject to the completion of due diligence and the execution of definitive agreements.
12
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward Looking Statements
This Quarterly Report on Form 10-Q/A, including this discussion and analysis by management, contains or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and our management’s beliefs and assumptions. In addition, other written or oral statements that constitute forward-looking statements may be made by or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We have included important factors in the cautionary statements below under the heading “Factors That May Affect Future Results” that we believe could cause our actual results to differ materially from the forward-looking statements we make. We do not intend to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Restatement
As further discussed in Note 2 to the condensed consolidated financial statements, we restated previously issued condensed consolidated financial statements for the three and six-months ended June 30, 2004. This restatement included pre-tax adjustments which totaled $60,000 and $266,000 for the three and six-months ended June 30, 2004, respectively, for amortization expense and asset impairment charges associated with customer relationship and trade name intangible assets.
The effect of recognizing customer relationship and trade name intangibles apart from goodwill resulted in out of period charges in the first quarter of 2004 for amortization expense of $70,000 and impairment charges of $77,000 which is included in the $266,000 restatement adjustment. The impact of these out of period charges to the consolidated statements of income and cash flows for fiscal 2002, 2003 and 2004 was not material. However, because the cumulative impact, if recorded in the fourth quarter of fiscal 2004, would have been material to net income for the fourth quarter of 2004, the Company restated its condensed consolidated financial statements for the quarters ended March 31, 2004, June 30, 2004 and September 30, 2004 as reported in Forms 10-Q/A.
In addition, we have revised our classification of intangible assets, and the associated income tax liabilities in the condensed consolidated balance sheets, which resulted in the recognition, apart from goodwill, of $2,143,271 and $2,580,000 of customer relationships and trade names, respectively, as of December 31, 2003. As part of the revised classification, in 2003 we recorded a deferred tax liability of $1,756,400 which relates to the book versus tax basis difference associated with these customer relationships and trade name assets. The deferred tax liability was recorded as a component of our purchase accounting for these acquisitions and accordingly increased goodwill by a corresponding amount. The impact of this revised classification and the recognition of the associated income tax liabilities to the condensed consolidated balance sheet was not material.
The effect of this restatement has been included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in this Form 10-Q/A.
Overview
We own and operate 37 dental laboratories located in 29 states, serving an active customer base of over 18,000 dentists. Our business consists of a single industry segment, which is the design, fabrication, marketing and sale of custom dental prosthetic appliances for dentists located primarily in the domestic marketplace. Product offerings include:
| • | Restorative products that are permanently affixed by a dentist to a patient’s existing dental anatomy, including traditional porcelain fused to metal crowns and bridges and dental implants. | |||
| • | Reconstructive products that are removable prostheses that replace missing teeth and associated structures, including partial and full dentures. | |||
| • | Cosmetic products that consist primarily of porcelain veneers designed to enhance the appearance of the front of a tooth as well as all-ceramic crowns that are made without a traditional metal substructure and more closely replicate the appearance of natural teeth. This category also includes composite inlays and onlays, which replace silver fillings for a more natural appearance and orthodontic appliances, which are products fabricated to move existing teeth to enhance function and appearance. | |||
Internal revenue growth has been relatively flat over the last three years. Early in 2001, we noted that the economic climate appeared to be impacting the dental laboratory industry. In 2002, we began to believe that many patients and dentists were postponing optimal treatment plans, such as crowns, and pursuing less expensive alternatives such as direct and indirect composite fillings, for
13
which we recognize no revenue. As a result, sales of restorative products were unfavorably impacted. We believe that while a portion of this segment can be temporarily deferred by patients, the work will eventually be required and will be done. During 2003, the economic situation was much like that in 2002, although we began to see some recent favorable signs in the marketplace that industry growth may have been returning to more positive trends. During the first and second quarters of 2004, we have seen internal sales growth stabilize and begin to grow. We are guardedly optimistic that sales growth will continue as economic conditions continue to improve.
We have also continued to pursue an acquisition strategy, which has played an important role in helping us increase sales from $75,680,000 in 2000 to $99,274,000 in 2003. However, operating margins as measured as a percentage of sales declined over this period. The main cost drivers for us are the cost of labor and related employee benefits. Competition for labor resources and increases in medical insurance costs drive these costs higher. These increased costs combined with flat internal sales growth contributed to lower operating margins. During 2003, we reviewed and adjusted staffing levels at each of our locations to minimize the costs of the slowdown in sales growth. We have been cautious about labor reductions due to the need to maintain an available and properly trained workforce in anticipation of future sales growth. During 2004, sales growth coupled with the cost containment efforts enacted in 2003 have improved operating margins in comparison to 2003.
Beginning in the fourth quarter of 2001 and continuing through 2004, we first developed and subsequently continued to invest in the “NDX Reliance Program™”, a national marketing and branding campaign that we believe holds long-term value and will help us attain our sales objectives. During 2004, we have continued to maintain our branding effort and have focused additional efforts on obtaining the measurable sales improvements we expect from this program.
Liquidity and Capital Resources
Our working capital increased from $12,252,000 at December 31, 2003 to $14,141,000 at June 30, 2004. Cash and equivalents increased $117,000 from $1,835,000 at December 31, 2003 to $1,952,000 at June 30, 2004. Operating activities provided $3,843,000 in cash flow for the six months ended June 30, 2004 compared to $2,539,000 during the six months ended June 30, 2003. Cash outflows related to dental laboratory acquisitions, including deferred purchase price payments, totaled $1,754,000 for the six months ended June 30, 2004 compared to $1,423,000 for the six months ended June 30, 2003. Additions to property, plant and equipment, including the purchase of a $2,000,000 replacement facility for our dental laboratory in Houston, Texas, were $2,480,000 for the six months ended June 30, 2004 compared to $1,557,000 for the six months ended June 30, 2003.
We have concluded a new financing agreement (the “Agreement”) with Fleet National Bank, a Bank of America company (the “Bank”). The Agreement, dated June 30, 2004, includes a revolving line of credit of $5,000,000 and a revolving acquisition line of credit of $20,000,000. The interest rate on both revolving lines of credit is the prime rate or, at our option, the London Interbank Offered Rate (“LIBOR”) or a cost of funds rate plus a range of 0.75% to 1.5% depending on the ratio of current liabilities to tangible net worth. Both revolving lines of credit terminate on June 30, 2007.
A commitment fee of one-eighth of 1% per annum is payable on the unused amount of the first revolving line of credit, plus an annual facility fee of $10,000 on the acquisition line of credit. At June 30, 2004, the full principal amount was available to us under both facilities. The Agreement requires compliance with certain covenants, including the maintenance of specified net worth and other financial ratios. As of June 30, 2004, we were in compliance with these covenants.
Our management believes that cash flow from operations and available financing arrangements will be sufficient to meet contemplated operating and capital requirements, including deferred payments associated with prior acquisitions and costs associated with anticipated acquisitions, if any, in the foreseeable future.
14
Commitments and Contingencies
The following table represents a list of our contractual obligations and commitments as of June 30, 2004 :
| Payments Due By Period | ||||||||||||||||||||
| Less Than | Greater Than | |||||||||||||||||||
| Total | 1 Year | 1 – 3 Years | 4 – 5 Years | 5 Years | ||||||||||||||||
| Operating Leases: | ||||||||||||||||||||
| Real Estate | $ | 8,556,000 | $ | 2,074,000 | $ | 2,985,000 | $ | 952,000 | $ | 2,545,000 | ||||||||||
| Vehicles | 953,000 | 334,000 | 619,000 | — | — | |||||||||||||||
| Equipment | 131,000 | 76,000 | 51,000 | 4,000 | — | |||||||||||||||
| Laboratory Purchase Obligations | 1,803,000 | 1,498,000 | 305,000 | — | — | |||||||||||||||
| Contingent Laboratory Purchase Price | 2,830,000 | 943,000 | 1,887,000 | — | — | |||||||||||||||
| TOTAL | $ | 14,273,000 | $ | 4,925,000 | $ | 5,847,000 | $ | 956,000 | $ | 2,545,000 | ||||||||||
The laboratory purchase obligations totaling $1,803,000 above are classified as deferred acquisition costs and are presented in the liability section of the balance sheet. Contingent laboratory purchase price includes amounts subject to acquisition agreements that are tied to earnings performance, as defined by the individual agreements, over a three year period. As payments become determinable, they are recorded as goodwill. We are committed under various non-cancelable operating lease agreements covering office space and dental laboratory facilities, vehicles and certain equipment. Certain of these leases also require us to pay maintenance, repairs, insurance and related taxes.
As sponsor of the National Dentex Corporation Dollars Plus Plan, (the “Plan”), a qualified plan under Section 401(a) of the Internal Revenue Code, we filed a retroactive plan amendment on April 22, 2004 under the Internal Revenue Service’s Voluntary Correction Program to clarify the definition of compensation in the Plan. Based on our consultation with our ERISA counsel, we believe this issue will be favorably resolved without requiring additional employer contributions or jeopardizing the tax-qualified status of the Plan.
Results of Operations
The following table sets forth for the periods indicated the percentage of net sales represented by certain items in our condensed consolidated financial statements:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30 | June 30 | |||||||||||||||
| 2003 | 2004 | 2003 | 2004 | |||||||||||||
| (Restated) | (Restated) | |||||||||||||||
| Net sales | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
| Cost of goods sold | 59.1 | 58.4 | 59.5 | 58.4 | ||||||||||||
| Gross profit | 40.9 | 41.6 | 40.5 | 41.6 | ||||||||||||
| Selling, general and administrative expenses | 29.9 | 29.5 | 30.3 | 30.7 | ||||||||||||
| Operating income | 11.0 | 12.1 | 10.2 | 10.9 | ||||||||||||
| Other expense | 0.2 | 0.4 | 0.3 | 0.3 | ||||||||||||
| Interest (income) expense | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||
| Income before provision for income taxes | 10.8 | 11.7 | 9.9 | 10.6 | ||||||||||||
| Provision for income taxes | 4.2 | 4.7 | 3.8 | 4.3 | ||||||||||||
| Net income | 6.6 | % | 7.0 | % | 6.1 | % | 6.3 | % | ||||||||
Six Months Ended June 30, 2004 Compared with Six Months Ended June 30, 2003
Net Sales
For the six months ended June 30 2004, net sales increased $7,612,000 or 15.5% from the prior year. Net sales increased by approximately $5,708,000, or 11.6%, as a result of acquisitions, measured by business at dental laboratories owned less than one year. Net sales increased approximately $1,904,000, an increase of 3.9%, at dental laboratories owned for both the six months ended June 30, 2004 and the comparable six months ended June 30, 2003. We believe sales growth was primarily attributable to a moderate improvement in industry economic conditions.
15
Cost of Goods Sold
Cost of goods sold as a percentage of sales was 58.4% in the six months ended June 30, 2004 compared with 59.5% in the same period of 2003. Headcount reductions, productivity improvements and purchasing cost savings helped improve our gross margin, despite increases in employee benefit and general insurance costs and the occupancy costs related to four acquisitions completed in the last half of 2003.
Selling, General and Administrative Expenses
Selling, general and administrative expenses, which consist of selling, delivery and administrative expenses both at the laboratory and corporate level, were $17,402,000 or 30.7% of sales in 2004 compared to $14,872,000 or 30.3% in 2003. The increase of $2,530,000 was related to the added administrative and delivery costs for recent acquisitions as well as the overall increases in insurance, benefits and utility costs. As a percentage of sales, declines in selling, delivery and laboratory administrative costs were offset by increases in our laboratory and executive incentive compensation programs. Improving profit margins resulting from sales growth and operational efficiencies increased our required contribution to these programs.
Beginning in 2004, we revised our classification of certain intangibles acquired through current and prior period business combinations. Specifically, the recognition of value as assigned to customer relationship intangibles resulted in amortization expense of approximately $189,000, of which approximately $70,000 relates to prior periods. Additionally, we recorded a charge of $77,000 to recognize impairment of acquired trade names in prior periods.
Operating Income
As a result of the factors discussed above, our operating income increased by $1,209,000 to $6,198,000 for the six months ended June 30, 2004 from $4,989,000 for the comparable six months ended June 30, 2003. As a percentage of net sales, operating income increased from 10.2% in 2003 to 10.9% in 2004.
Interest (Income) Expense
Interest expense was $18,000 in the first six months of 2004 compared with interest income of $16,000 in the first six months of 2003. The change of $34,000 was primarily due to periodic borrowings under the line of credit during 2004 and a decrease in the average cash and cash equivalents balance from 2003 to 2004.
Provision for Income Taxes
The provision for income taxes increased to $2,402,000 in 2004 from $1,894,000 in 2003 due to an increase in operating income and a higher effective tax rate. The effective tax rate increased to 40.0% in 2004 from 38.8% in 2003 due to expected increases in non-deductible expenses.
Net Income
As a result of all of the factors discussed above, net income increased to $3,603,000 or $.66 per share on a diluted basis in the first six months of 2004 from $2,982,000 or $.58 per share on a diluted basis in the first six months of 2003.
Three Months Ended June 30, 2004 Compared with Three Months Ended June 30, 2003
Net Sales
For the three months ended June 30, 2004, net sales increased $3,649,000 or 14.5% from the prior year. Net sales increased by approximately $2,928,000, or 11.6%, as a result of acquisitions, measured by business at dental laboratories owned less than one year. Net sales increased approximately $721,000, an increase of 2.9%, at dental laboratories owned for both the three months ended June 30, 2004 and the comparable three months ended June 30, 2003.
Cost of Goods Sold
Cost of goods sold as a percentage of sales was 58.4% in the quarter ended June 30, 2004 compared with 59.1% in the same period of 2003 for reasons comparable to the six-month period discussed above.
16
Selling, General and Administrative Expenses
Selling, general and administrative expenses, which consist of selling, delivery and administrative expenses both at the laboratory and corporate level, were $8,517,000 or 29.5% of sales in 2004 compared to $7,528,000 or 29.9% in 2003 for reasons comparable to the six-month period discussed above.
Operating Income
As a result of the factors discussed above, and for reasons comparable to the six-month period discussed above, our operating income increased by $707,000 to $3,485,000 for the three months ended June 30, 2004 from $2,778,000 for the comparable three months ended June 30, 2003. As a percentage of net sales, operating income increased from 11.0% in 2003 to 12.1% in 2004.
Interest (Income) Expense
Interest expense was $7,000 in the second quarter of 2004 compared with interest income of $7,000 in the second quarter of 2003 for reasons comparable to the six-month period discussed above.
Provision for Income Taxes
The provision for income taxes increased to $1,348,000 in 2004 from $1,058,000 in 2003 and the effective tax rate increased to 40.0% in 2004 from 39.1% in 2003 for reasons comparable to the six-month period discussed above.
Net Income
As a result of all of the factors discussed above, net income increased to $2,022,000 or $.37 per share on a diluted basis in the second quarter of 2004 from $1,650,000 or $.32 per share on a diluted basis in the second quarter of 2003.
Factors That May Affect Future Results
Various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, statements contained in this Quarterly Report on Form 10-Q/A, including, but not limited to, the following:
| • | the timing, duration and effects of adverse changes in overall economic conditions, particularly those affecting employment patterns or likely to cause individuals to defer needed or elective dental work, | |||
| • | our ability to acquire and successfully operate additional laboratories, | |||
| • | governmental regulation of health care, | |||
| • | trends in the dental industry towards managed care, | |||
| • | competition within the dental laboratory industry, including from foreign competitors, | |||
| • | increases in labor and benefits costs, | |||
| • | increases in material costs, particularly related to the purchase of dental alloys, which contain gold, palladium, and other precious metals, | |||
| • | product development risks, and | |||
| • | technological innovations by third parties. | |||
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our market risk exposure includes potential price volatility of commodities we use in our manufacturing processes. We purchase dental alloys that contain gold, palladium and other precious metals. We have not participated in hedging transactions. We have relied on pricing practices that attempt to pass increased costs on to the customer, in conjunction with materials substitution strategies.
17
Item 4. Controls and Procedures
(a)Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act) as of June 30, 2004. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our CEO and CFO concluded that, as of June 30, 2004, our disclosure controls and procedures were (1) designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our CEO and CFO by others within those entities, particularly during the period in which this report was being prepared and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
Management’s Consideration of the Restatement
In concluding that our internal control over financial reporting was effective as of December 31, 2004 as summarized in Item 9A of our Form 10-K for the year ended December 31, 2004, our management considered, among other things, the control deficiency related to the accounting for business combinations, which resulted in the need to restate our previously issued condensed consolidated financial statements for the first three fiscal quarters of fiscal 2004. After reviewing and analyzing the Commission’s Staff Accounting Bulletin (“SAB”) No. 99, “Materiality,” Accounting Principles Board Opinion No. 28, “Interim Financial Reporting,” paragraph 29 and SAB Topic 5 F, “Accounting Changes Not Retroactively Applied Due to Immateriality,” and taking into consideration (i) that the restatement adjustments did not have a material impact on the financial statements of prior interim or annual periods taken as a whole; (ii) that the cumulative impact of the restatement adjustments on stockholders’ equity was not material to the financial statements of prior interim or annual periods; and (iii) that National Dentex decided to restate its previously issued financial statements solely because the cumulative impact of the error, if recorded in the fourth quarter of 2004, would have been material to the current quarter’s reported net income, management concluded that the control deficiency that resulted in the restatement of the financial statements for the first three fiscal quarters of fiscal 2004, was not, in itself, a material weakness. Furthermore, management concluded that the control deficiency that resulted in the restatement when aggregated with other deficiencies did not constitute a material weakness.
(b)Changes in Internal Controls.
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act) occurred during the fiscal quarter ended June 30, 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NATIONAL DENTEX CORPORATION | ||||
| Registrant | ||||
| May 24, 2005 | ||||
| By: | /s/ DAVID L. BROWN | |||
| David L. Brown | ||||
| President, CEO and Director | ||||
| (Principal Executive Officer) | ||||
| May 24, 2005 | ||||
| By: | /s/ RICHARD F. BECKER, JR. | |||
| Richard F. Becker, Jr. | ||||
| Vice President, Treasurer and Chief Financial Officer | ||||
| (Principal Financial Officer) | ||||
19
Exhibit Index
| Exhibit | ||
| No. | Description | |
| 31.1 | Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act (Chief Executive Officer). | |
| 31.2 | Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act (Chief Financial Officer). | |
| 32.1 | Certification pursuant to 18 U.S.C. Section 1350 (Chief Executive Officer) | |
| 32.2 | Certification pursuant to 18 U.S.C. Section 1350 (Chief Financial Officer) |
20